



1FW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/632,366
Filing Date	July 31, 2003
First Named Inventor	Cooper G.
Art Unit	1632
Examiner Name	To be Assigned
Attorney Docket Number	49123-000033.UTL1

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO-SB08,136 documents, return postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	James W. Collett, Ph.D.
Signature	
Date	07/30/04

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Johann Lin		
Signature		Date	07/30/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



49123.000033.UTL1
U.S. PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)	Group Art Unit: 1632
)	
Cooper et al)	Examiner: To be Assigned
)	
Serial No.: 10/632,366)	Confirmation No.: 3985
)	
Filed: July 31, 2003)	Customer. No. 23464
)	
For: METHODS OF USE OF)	
COMPOUNDS WITH)	
PREPTIN FUNCTION)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97-1.98

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to receipt of a first Office Action on the merits with respect to the above-captioned application. Thus, it is believed that there is no fee due for filing this statement. However, any fees that may be due in connection with filing this statement may be charged to Deposit Account No. 02-4553.

In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Forms PTO-SB/08 (11 pages), is provided herewith.

The Examiner's attention is directed to the following U.S. and international applications:

<u>U.S.S.N. (App. No.)</u>	<u>Filing Date</u>
09/745,078	12/20/2000
10/374,624	11/26/2002


<u>Int'l App. No.</u>	<u>Filing Date</u>	<u>Int'l Pub. No.</u>
PCT/NZ00/00102	06/19/2000	WO/00/78805
PCT/NZ2003/000168	07/31/2003	WO/2004/012760
PCT/NZ2003/000171	08/01/2003	WO/2004/012761

The filing of this Information Disclosure Statement is not to be construed as an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and information and that they be made of record in the file history of the above-captioned application.


Respectfully submitted,

BUCHANAN INGERSOLL L.L.P.

By: 
James W. Collett
Reg. No. 46,636

One Oxford Centre
301 Grant Street
Pittsburgh, PA 15219-1410
(O) (619) 578.5000
(F) (619) 578.5940

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	1	of	11	Attorney Docket Number	49123.000033.UTL1

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1)	US20030203973		Cooper et al.	10-30-2003
	2)	US20030186946		Cooper et al.	10-02-2003
	3)	US20030166561		Cooper et al.	09-04-2003
	4)	US20030064918		Reid et al.	04-03-2003
	5)	US20030050434		Cooper et al.	03-13-2003
	6)	US20020197596		Cooper et al.	12-26-2002
	7)	6,048,514		Young et al.	04-11-2000
	8)	5,942,227		Cooper et al.	08-24-1999
	9)	5,716,619		Cooper et al.	02-10-1998
	10)	5,641,744		Cooper et al.	1997-06-24
	11)	5,367,052		Cooper et al.	11-22-1994
	12)	5,364,841		Cooper et al.	11-15-1994
	13)	5,281,581		Cooper et al.	01-25-1994
	14)	5,280,014		Cooper et al.	01-18-1994
	15)	5,266,561		Cooper et al.	11-30-1993
	16)	5,260,275		Cooper et al.	11-09-1993
	17)	5,234,906		Young et al.	08-10-1993
	18)	5,175,145		Cooper et al.	12-29-1992
	19)	5,124,314		Cooper G.	06-23-1992
	20)	4,816,567		Cabilly et al.	03-28-1989
	21)	4,767,628		Hutchinson	08-30-1988
	22)	3,773,919		Boswell et al.	11-20-1973

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document by the two-letter code (WPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if known			
		Application Number	10/632,366		
		Filing Date	July 31, 2003		
		First Named Inventor	Cooper		
		Group Art Unit	1632		
		Examiner Name	TBA		
Sheet	2	of	11	Attorney Docket Number	49123.000033.UTL1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	T
		Number ⁴	Kind Co (if known)			
	23)	AU-A-21575/88		Amylin Corporation	07/20/1989	Eqv. (19)*
	24)	AU29494/89		Amylin Corporation	07/27/1989	Eqv. (47)*
	25)	AU59537/90		Amylin Corporation	02/06/1991	Eqv. (46)*
	26)	AU13286/92		Amylin Pharmaceuticals, Inc.	07/23/1992	Eqv. (17)*
	27)	EP 0289287		Cooper et al.	01-28-1998	
	28)	EP 0787741		AMYLIN PHARMACEUTICALS, INC.	08-06-1997	
	29)	EP 0309 100		Cooper G.	07-23-1997	
	30)	EP 0332 435		Zeneca Limited	10-13-1999	
	31)	WO2004017957 A1		Cooper et al.	03-04-2004	
	32)	WO2004017956		Cooper et al.	03-04-2004	
	33)	WO2004012761 A1		Cooper et al.	02-12-2004	
	34)	WO2004012760		Cornish et al.	02-12-2004	
	35)	WO2003093311 A1		Cooper et al.	11-13-2003	
	36)	WO2003077901 A1		Cooper et al.	09-25-2003	
	37)	WO2003075910 A1		Cooper et al.	09-18-2003	
	38)	WO2003074559 A1		Cooper et al.	09-12-2003	
	39)	WO2003062275 A1		Cooper et al.	07-31-2003	
	40)	WO2003045424 A1		Cooper G.	06-05-2003	
	41)	WO2002079785 A2		Cooper et al.	10-10-2002	
	42)	WO0078805		Cooper et al.	12-28-2000	
	43)	WO0058348		Cornish et al.	10-05-2000	
	44)	WO9415587		Kinerton Limited	07-21-1994	
	45)	WO9211862		Young et al.	07-23-1992	
	46)	WO9100737		Cooper et al.	01-24-1991	
	47)	WO8906135		Cooper et al.	07-13-1989	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.* Copies of corresponding US or PCT equivalents provided. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	3	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	48)	ALTSCHUL et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, 1997, Vol. 25, No. 17, pp. 3389-3402		
	49)	AMERICAN DIABETES ASSOCIATION, "Economic Consequences of Diabetes Mellitus in the U.S. in 1997", Diabetes Care, Vol. 21, No. 2, February 1998, pp. 296-309		
	50)	ARGOURD et al., "Insulin Suppresses Its Own Secretion In Vivo", Diabetes, Vol. 36, August 1987, pp. 959-962		
	51)	ARVINTE et al., "The Structure and Mechanism of Formation of Human Calcitonin Fibrils", The Journal of Biological Chemistry, Vol. 268, No. 9, Issue of March 25, 1993, pp. 6415-6422		
	52)	BAI et al., "Role of Ca ²⁺ in apoptosis evoked by human amylin in pancreatic islet β-cells", Biochem. J., 343, 53-61, (1999) (Great Britain)		
	53)	BAUER et al., "Architecture and Polymorphism of Fibrillar Supramolecular Assemblies Produced by <i>in Vivo</i> Aggregation of Human Calcitonin", Journal of Structural Biology, 115, 1-15 (1995)		
	54)	BELL et al., "Sequence of a Cdna clone encoding human preproinsulin-like growth factor II", Nature, Vol. 310, 30 August 1984, pp. 775-777		
	55)	BELL et al., "Isolation of the human insulin-like growth factor genes: Insulin-like growth factor II and insulin genes are contiguous", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 6450-6454, October 1985		
	56)	BREMER et al., "Negative Staining", Cell Biology, Second Edition, Volume 3, pp. 277-284		
	57)	BRYSON et al., "Production of insulin-like growth factor-II by human fetal pancreas in culture", Journal of Endocrinology (1989) 121, 367-373		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	4	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examine Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	58)	BUCHANAN et al., "Preptin derived from proinsulin-like growth factor II (proIGF-11) is secreted from pancreatic islet β-cells and enhances insulin secretion", Biochem. J. (2001) 360, 431-439 (Great Britain)		
	59)	BUCK et al., "Monoclonal Antibodies Specific for Cell Culture Mycoplasmas", IN VITRO, Vol. 18, No. 4, April 1982, pp. 377-381		
	60)	CHEMCATS Acc. No. (AN) 1998:22309, Advanced Chem Tech Product Catalog (10 June 1999); CAS Reg. No. (RN) 198757-90-3 (Abstract)		
	61)	Clark A, et al.; "Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes." Diabetes Res. 1988 Dec;9(4):151-9.		
	62)	COCKETT et al., "High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification", Bio/Technology, Vol. 8, July 1990, pp. 662-667		
	63)	COOPER et al., "Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 7763-7766, October 1988		
	64)	COOPER, "A reappraisal of current hypotheses concerning the possible roles of amylin in physiology, pathology and therapeutics", Clinical Science Regional Focus Series, pp. 7-12		
	65)	COOPER, "Amylin and Insulin Co-replacement Therapy for Insulin-Dependent (Type 1) Diabetes Mellitus", Medical Hypotheses (1991) 36, 284-288, Longman Group UK Ltd. 1991		
	66)	COOPER, "Amylin Compared with Calcitonin Gene-Related Peptide: Structure, Biology, and Relevance to Metabolic Disease", Endocrine Reviews, Vol. 15, No. 2, USA, pp. 163-201		
	67)	COOPER et al., "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 8628-8632, December 1987		
	68)	COOPER et al., "Amylin Hormone", Nature, Vol. 340, July 27, 1988		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	5	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	69)	COOPER, "Therapeutic Potential of Human Amylin Analogues in Diabetes Mellitus", BioDrugs, 1998 Jul 10(1), pp. 1-9		
	70)	COOPER, "Amylin and related proteins: physiology and pathophysiology", Handbook of Physiology, Section 7, Vol. II, pp. 303-396		
	71)	DAUGHADAY et al., "Heterogeneity of Serum Peptides with Immunoactivity Detected by a Radioimmunoassay for Proinsulin-Like Growth Factor-II E Domain: Description of a Free E Domain Peptide in Serum", Journal of Clinical Endocrinology and Metabolism, Vol. 75, No. 2, pp. 641-645		
	72)	DAVIDSON et al., "The insulin-secretory-granule carboxypeptidase H", Biochem. J. (1987) 245, 575-582 (Great Britain)		
	73)	DeCHIARA et al., "A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting", Nature, Vol. 345, 3 May 1990, pp. 78-80		
	74)	DeFRONZO et al., "Pathogenesis of NIDDM", Diabetes Care, Vol. 15, No. 3, March 1992, pp. 318-368		
	75)	DEGAN, "Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas", Regulatory Peptides, 43 (1993) 91-96		
	76)	DEVI, "Consensus sequence for processing of peptide precursors at monobasic sites", FEBS 09502, Vol. 280, No. 2, 189-194 (March 1991)		
	77)	DUGUAY et al., "Post-translational Processing of the Insulin-like Growth Factor-2 Precursor", The Journal of Biological Chemistry, Vol. 273, No. 29, Issue of July 17, pp. 18443-18451, 1998		
	78)	DULL et al., "Insulin-like growth factor II precursor gene organization in relation to insulin gene family", Nature, Vol. 310, 30 August 1984, pp. 777-781		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	6	of	11	Attorney Docket Number	49123.0000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	79)	EFRAT et al., "Murine Insulinoma Cell Line with Normal Glucose-Regulated Insulin Secretion", Diabetes, Vol. 42, June 1993, pp. 901-907	
	80)	ELAHI et al., "Feedback Inhibition of Insulin Secretion by Insulin: Relation to the Hyperinsulinemia of Obesity", The New England Journal Of Medicine, May 20, 1982, pp. 1196-1202	
	81)	THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS, "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus", Diabetes Care, Vol. 20, No. 7, July 1997	
	82)	GAMMELTOFT et al., "Insulin-like growth factors and insulin: gene expression, receptors and biological actions", Peptide Hormones As Prohormones", Halstead Press, pp. 176-197	
	83)	GILL, et al., "Calculation of Protein Extinction Coefficients from Amino Acid Sequence Data", Analytical Biochemistry 182, 319-326 (1989), pp. 319-326	
	84)	GOLDSBURY et al., "Amyloid Fibril Formation from Full-Length and Fragments of Amylin", Journal of Structural Biology, 130, 352-362 (2000)	
	85)	GOLDSBURY et al., "Watching Amyloid Fibrils Grow by Time-lapse Atomic Force Microscopy", J. Mol. Biol. (1999) 285, 33-39	
	86)	GOLDSBURY et al., "Polymorphic Fibrillar Assembly of Human Amylin", Journal of Structural Biology 119, 17-27 (1997) Article No. SB973858	
	87)	GOTOH, et al., "Reproducible High Yield of Rat Islets by Stationary in Vitro Digestion Following Pancreatic Ductal or Portal Venous Collagenase Injection", Transplantation, Vol. 43, No. 5, pp. 725-730	
	88)	GREENFIELD, "Methods to Estimate the Conformation of Proteins and Polypeptides from Circular Dichroism Data", Analytical Biochemistry, 235, 1-10 (1996), Article No. 0084	
Examiner Signature			Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if known			
		Application Number	10/632,366		
		Filing Date	July 31, 2003		
		First Named Inventor	Cooper		
		Group Art Unit	1632		
		Examiner Name	TBA		
Sheet	7	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	89)	GRIFFITHS et al., "Rotational Resonance Solid-State NMR Elucidates a Structural Model of Pancreatic Amyloid", J. Am. Chem. Soc. 1995, 117, 3539-3546	
	90)	Grodsky et al., "The <i>in vitro</i> Perfused Pancreas", Methods in Enzymology, Vol. 39., 1975, pp. 364-372	
	91)	GUEST et al., "Insulin Secretory Granule Biogenesis", Biochem. J. (1991) 274, 73-78 (Great Britain)	
	92)	HETTIARACHCHI et al., "Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats", Am. J. Physiol. 273 (Endocrinol. Metab.36): E859-E867, 1997.	
	93)	HODGSON, "Making Monoclonals in Microbes", Bio/Technology, Vol. 9, May 1991, pp. 421, 425	
	94)	HOOG et al., "Ultrastructural Localization of Insulin-like Growth Factor-2 (IGF-2) to the Secretory Granules of Insulin Cells: A Study in Normal and Diabetic (GK) Rats", Ultrastructural Pathology, 21:457-466, 1997	
	95)	HOOG et al., "A high-molecular IGF-2 immunoreactive peptide (pro-IGF-2) in the insulin cells of the islets of Langerhans in pancreas of man and rat", Regulatory Peptides, 47 (1993) 275-283	
	96)	HUNTER et al., "A case of hepatoma associated with hypoglycaemia and overproduction of IGF-II (E-21): beneficial effects of treatment with growth hormone and intrahepatic adriamycin", Clinical Endocrinology (1994) 41, 397-401	
	97)	HUTTON, "The insulin secretory granule", Diabetologia (1989) 32:271-281	
	98)	HUTTON, "Isolation and Characterisation of Insulin Secretory Granules from a Rat Islet Cell Tumour", Diabetologia (1982) 365-373	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	8	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	99)	HYLKA et al., "Identification of a Peptide Fragment from the Carboxyl-terminal Extension Region (E-domain) of Rat Proinsulin-like Growth Factor-II", The Journal of Biological Chemistry, Vol. 260, No. 27, Issue of November 25, pp. 14417-14420, 1985	
	100)	JOHNSON et al., "Immunolocalization of Islet Amyloid Polypeptide (IAPP) in Pancreatic Beta Cells by Means of Peroxidase-Antiperoxidase (PAP) and Protein A--Gold Techniques", American Journal of Pathology, Vol. 130, No. 1, January 1988, pp. 1-8	
	101)	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>in Vitro</i> ", J. Mol. Biol. (1999) 287, 781-796	
	102)	KELLY, The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways", Current Opinion in Structural Biology, 1998, 8:101-106	
	103)	KNAACK et al., "Clonal Insulinoma Cell Line that Stably Maintains Correct Glucose Responsiveness", Diabetes, Vol. 43, December 1994, 1413-1417	
	104)	KUDVA et al., "A novel assay <i>in vitro</i> of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation", Biochem J. (1998) 331, 809-813 (Great Britain)	
	105)	KULKARNI et al., "Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes", Cell, Vol. 96, 329-339, February 5, 1999	
	106)	LeVINE, "Thioflavine T interaction with synthetic Alzheimer's disease β -amyloid peptides: Detection of amyloid aggregation in solution", Protein Science (1993), 2, 404-410, Cambridge University Press	
	107)	LINDE et al., "Reversed-Phase High-Performance Liquid Chromatographic Analyses of Insulin Biosynthesis in Isolated Rat and Mouse Islets", Journal of Chromatography, 462 (1989) 243-254	
	108)	LIU et al., "Characterization of Proinsulin-Like Growth Factor-II E-Region Immunoreactivity in Serum and Other Biological Fluids", Journal of Clinical Endocrinology and Metabolism, Vol. 76, No. 5, pp. 1095-1100	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	9	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	109)	LORENZO et al., "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus", Nature, Vol. 368, 21 April 1994, pp. 756-760	
	110)	MARGLIN et al., "Chemical Synthesis of Peptides and Proteins", Annu. Rev. Biochem., July 1970, Vol. 39, pp. 841-866	
	111)	MOORE, et al., "Co-Secretion of Amylin and Insulin from Cultured Islet β -Cells: Modulation by Nutrient Secretagogues, Islet Hormones and Hypoglycemic Agents", Biochemical and Biophysical Research Communications, Vol. 179, No. 1, 1991, August 30, 1991, pp. 1-9	
	112)	Müller et al., "Factors influencing the precision of quantitative scanning transmission electron microscopy", Ultramicroscopy 46 (1992) 317-334, North Holland	
	113)	Ong et al., "The insulin gene VNTR, type 2 diabetes and birth weight", Nature Genetics, Vol. 21, March 1999, pp. 262-263	
	114)	ORITA, et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 2766-2770, April 1989	
	115)	PEARSON, "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, Vol. 183, pp. 63-98	
	116)	REDD et al., "A Complex Composed of Tup1 and Ssn6 Represses Transcription <i>in Vitro</i> ", The Journal of Biological Chemistry, Vol. 272, No. 17, Issue of April 25, pp. 11193-11197, 1997	
	117)	REED et al., "A Set of Constructed Type Spectra for the Practical Estimation of Peptide Secondary Structure from Circular Dichroism", Analytical Biochemistry 254, 36-40 (1997)	
	118)	ROBBINS et al., "The Kidney", Pathologic Basis of Disease, Third Edition, 1984, W. B. Saunders Co., pp. 991-1061	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	10	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	119)	ROBERTS et al., "Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 9662-9666, December 1989	
	120)	ROMANUS et al., "Synthesis of Insulin-Like Growth Factor II (IGF-II) in Fetal Rat Tissues: Translation of IGF-II Ribonucleic Acid and Processing of Pre-Pro-IGF-II", Endocrinology, Vol. 122, No. 2, pp. 709-716	
	121)	RUDINGER, "Characteristics of the Amino Acids As Components of a Peptide Hormone Sequence", Peptide Hormones, University Park Press, June 1976, pp. 1-7	
	122)	SILVESTRE et al., "Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat", British Journal of Pharmacology (1996) 117, 347-350	
	123)	STEMPIEN et al., "Sequence of a Placental cDNA Encoding the Mouse Insulin-Like Growth Factor II Precursor", DNA, Volume 5, Number 5, pp. 357-361, 1986	
	124)	TALLY et al., "Immunoreactive Proinsulin-Like Growth Factor-II Levels in Healthy Subjects, Patients with Growth Hormone Deficiency, and Patients with Type 1 Diabetes: Effects of Insulin-Like Growth Factor-I and Insulin", Journal of Clinical Endocrinology and Metabolism, Vol. 79, No. 6, pp. 1576-1581	
	125)	TATEMOTO et al., "Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion", Nature, Vol. 324, December 4, 1986, pp. 476-478	
	126)	TENIDIS et al., "Identification of a Penta- and Hexapeptide of Islet Amyloid Polypeptide (IAPP) with Amyloidogenic and Cytotoxic Properties", J. Mol. Biol. (2000) 295, 1055-1071	
	127)	WAGONER et al., "Amylin modulates β -cell glucose sensing via effects on stimulus--secretion coupling", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 9145-9149, October 1993	
	128)	WANG et al., "h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo", FEBS 10256, Vol. 291, No. 2, 195-198, October 1991	
	129)	WESTERMARK et al., "Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 3881-3885, June 1987	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/02. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/632,366
				Filing Date	July 31, 2003
				First Named Inventor	Cooper
				Group Art Unit	1632
				Examiner Name	TBA
Sheet	11	of	11	Attorney Docket Number	49123.000033.UTL1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	130)	WESTERMARK et al., "Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 5036-5040, July 1990	
	131)	WOLLHEIM et al., "Regulation of Insulin Release by Calcium", Physiological Reviews, Vol. 61, No. 4, October 1981, pp. 914-973	
	132)	YANG et al., "Calculation of Protein Conformation from Circular Dichroism", Methods in Enzymology, Vol. 130, pp. 208-269 (1986)	
	133)	Zapf et al., "Radioimmunological Determination of Insulinlike Growth Factors I and II in Normal Subjects and in Patients with Growth Disorders and Extrapaneatic Tumor Hypoglycemia", J. Clin. Invest., Vol. 68, November 1981 1321-1330	
	134)	ZHANG et al., "Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21 ^{WAF1/CIP1} ", FEBS Letters 455 (1999) 315-320	
	135)	ZUMSTEIN et al., "Amino Acid Sequence of a Variant Pro-Form of Insulin-Like Growth Factor II", Proceedings of the National Academy of Sciences of the United States of America, Vol. 82, No. 10 (May 15, 1985), 3169-3172	
	136)	Reid et al., "Relationships among body mass, its components, and bone". Bone. 2002 Nov;31(5):547-55.	
	137)	Trumper et al., Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001 Sep;15(9):1559-70	
	138)	ZhouJ. Et al.; "Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells." Diabetes. 1999 Dec;48(12):2358-66	
	139)	Abraham et al. "Endocrine-related resourses from the National Institute of Health" Endocrinology 143 (8):3200-3202	
	140)	Risbud M and Bhonde; "Models of Pancreatic regeneration in Diabetes" Diabetes Research and Clinical Practice 58 (2002): 155-165.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.